Jubilant Ingrevia is fully committed towards its growth aspiration and the company is excited to realize the emerging opportunities through its ongoing Capex plan of Rs. 2,050 crore during FY '22 to FY '25,  says Rajesh Srivastava, CEO and Managing Director, Jubilant Ingrevia Limited speaking at Q2 FY 2023 Earnings Conference Call.  

"We continue our efforts towards improving our revenue mix of the Specialty and Nutrition segment to 65% by FY '27 from 46% in FY'22, and we believe this to be a key driver for overall margin improvements," commented Srivastava.

"We expect our H2 performance to be better than H1, assuming no unexpected adverse situation. We expect overall healthy revenue growth during

FY '23, led by volume growth in Specialty Chemicals and Chemical Intermediates segments. Commissioning of new Capex during H2 is likely to aid the growth," said Srivastava.

"Most of our new growth Capex investments are happening on the Specialty Chemicals and Nutrition side. The new investments will bring additional revenues, which will change the entire revenue profile of Specialty and Nutrition. On the Chemical Intermediates side, as you can see, our major Capex is on Anhydride and on Green Acetic Acid. Rest all growth Capex are in the Specialty and Nutrition side. And therefore, the change in mix will happen with that," added Srivastava.

Jubilant Ingrevia, a global integrated life science products and innovative solutions provider serving pharmaceutical, nutrition, agrochemical, consumer, and Industrial customers with customized products and solutions that are innovative, cost-effective, and conforming to excellent quality standards.

Globally #1 in Pyridine and #1 in 11 Pyridine derivatives, Jubilant Ingrevia Limited offers a broad portfolio of high-quality ingredients that find application in a wide range of industries. The company’s portfolio also extends to custom development and manufacturing for pharmaceutical and agrochemical customers on an exclusive basis.